FDA approves Epclusa for pediatric HCV

Epclusa is now available for the treatment of children with any of the six genotypes of hepatitis C virus after obtaining approval from the FDA, according to a press release.Previously approved to treat HCV in adults, Epclusa (sofosbuvir/velpatasvir, Gilead Sciences) is indicated in pediatric patients aged 6 years and older or weighing at least 37 pounds.“This approval will provide additional treatment options for children and adolescents with HCV,” Debra Birnkrant, MD, director of the division of antivirals in the FDA’s Center for Drug Evaluation and Research, said in theRead More

Share on facebook
Share on twitter
Share on linkedin